Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
Epistemonikos ID: b1a52b9a84996ebaa5e6bd4c5826ec01a26435f4
First added on: Jul 10, 2018